Biocartis aiming for 100 to 125 million

April 2, 2015 News BioVox

In the second week of the Easter holidays, Biocartis will launch its IPO. According to experts it aims at raising 100-125 million euros, double what was raised privately in September. Since its foundation in 2007, the company has already acquired about 250 million euros. Biocartis is the most high profile biotechnology company in Flanders.

Founder Rudi Pauwels was previously at the forefront of HIV-blockers Tibotec and Virco, and underlies the origin of Galagapos and MDxHealth. In 2002 he sold Tibotec and Virco, and Johnson & Johnson bought both businesses. Pauwels founded Biocartis in Switzerland, but  Flemish research institutes and venture capital have brought it back to Belgium. Pauwels is grateful for that: “In Switzerland, we could not have done what we have done here.”

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts


* indicates required

Intuit Mailchimp